Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2).
An increasing demand in livestock animal husbandry for intervention or emergency vaccination strategies requires a rapid onset of protection linked to prevention of infectious agent spread. Using the new recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E2 glycoprotein we demonstrate that a single intra-muscular application confers solid protection. In the prime only concept, multi-site application of the vector vaccine turned out to be superior to single-site application as no pyrexia occurred after virulent CSFV challenge and CSFV neutralizing serum antibodies regularly were detectable before challenge. Vector virus vaccinated swine were able to cope with the lymphocyte and in particular B-cell depression in peripheral blood after challenge showing no clinical signs and no viremia. Early after challenge CSFV-specific IFN gamma production (IFN-gamma) and high neutralizing serum antibody titers clearly differentiated naïve from vaccinated and protected animals. After CSFV challenge neutralizing serum antibodies titers in vector vaccinated swine were significantly higher than those in sera from live attenuated vaccine primed animals. Horizontal challenge virus transmission was prevented under strict sentinel isolation before mingling but not in next-door stables separated by a wooden barrier at the day of challenge. The presence of CSFV-specific pre-challenge serum antibodies although in low titers is a good prognostic parameter for solid protection after ORFV vector vaccination even when a significant CSFV-specific IFN-gamma production was not detectable before challenge. A heterologous prime-boost regimen as a combination of prime with baculovirus-expressed glycoprotein E2 followed by boost with the parapoxvirus vector turned out to be a better immune stimulant than a homologous prime/boost with the modified live CSFV vaccine. A similar beneficial effect became evident when the challenge infection mimicked the booster vaccination after a single PPV vector prime.
Voigt
Heiner
H
Friedrich-Loeffler-Institut, Institute for Immunology, Tübingen, Germany.
Merant
Catherine
C
Wienhold
Daniel
D
Braun
Angelika
A
Hutet
Evelyne
E
Le Potier
Marie-Frédérique
MF
Saalmüller
Armin
A
Pfaff
Eberhard
E
Büttner
Mathias
M
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002460:Cell Line; D006691:Classical Swine Fever / Q000517:prevention & control*; D006692:Classical Swine Fever Virus / Q000276:immunology*; D009923:Orf virus / Q000276:immunology*; D011994:Recombinant Proteins; D012449:Safety; D013552:Swine; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C087086:glycoprotein E2, classical swine fever virus